Fig. 4: CD388 efficacy in lethal mouse models of influenza A and B harbouring NA mutations that confer reduced susceptibility to other NAIs.
From: Drug–Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice
a–c, Efficacy of CD388 administered i.m. at the indicated doses at 2 h post infection against influenza A/Texas/23/2012 (H1N1)pdm09 NA H275Y variant (a), ZAN-susceptible influenza B/Laos/0080/2016 (Victoria) (b) and ZAN-resistant B/Laos/0654/2016 NA H134N variant (Victoria) (c) in BALB/c mice (n = 5 per group). d,e, Comparisons of dose responses of ZAN administered intranasally starting at 2 h post infection for 5 days and CD388 administered i.m. once at 2 h post infection at 0.3 mg kg−1 to ZAN-susceptible influenza B/Laos/0080/2016 (d) and ZAN-resistant B/Laos/0654/2016 NA H134N (e) variants in BALB/c mice (n = 5 per group).
